目的 探討癲癇寧片聯(lián)合奧卡西平片治療癲癇的臨床療效。方法 選取2021年1月-2022年1月在海南省老年病醫(yī)院就診的94例癲癇患者，按照計(jì)算機(jī)隨機(jī)排列分為對(duì)照組和治療組，各47例。對(duì)照組患者口服奧卡西平片，起始劑量1片/次，2次/d，每隔1周增加藥物劑量，每次增加2片，分為2次口服，維持劑量2~8片/d。治療組在對(duì)照組基礎(chǔ)上口服癲癇寧片，4片/次，3次/d。兩組連續(xù)治療3個(gè)月。觀察兩組的臨床療效，比較兩組的強(qiáng)直發(fā)作頻率、陣攣發(fā)作頻率、癇樣放電數(shù)、累及導(dǎo)聯(lián)數(shù)、棘波指數(shù)以及血清神經(jīng)元特異性烯醇化酶（NSE）、白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）水平。結(jié)果 治療后，治療組的總有效率為91.49%，對(duì)照組的總有效率為74.47%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組強(qiáng)直發(fā)作頻率、陣攣發(fā)作頻率明顯低于治療前（P<0.05）；治療后治療組強(qiáng)直發(fā)作頻率、陣攣發(fā)作頻率明顯低于對(duì)照組（P<0.05）。治療后，兩組的癇樣放電數(shù)、累及導(dǎo)聯(lián)數(shù)、棘波指數(shù)顯著降低（P<0.05）；治療后治療組的癇樣放電數(shù)、累及導(dǎo)聯(lián)數(shù)、棘波指數(shù)低于對(duì)照組（P<0.05）。治療后，兩組的血清NSE、IL-1β、TNF-α水平低于治療前（P<0.05），治療組血清NSE、IL-1β、TNF-α水平較對(duì)照組更低（P<0.05）。結(jié)論 癲癇寧片聯(lián)合奧卡西平片能顯著提高癲癇的臨床療效，減輕癲癇癥狀、腦部異常放電和神經(jīng)細(xì)胞的炎癥損傷。

Objective To investigate the clinical effect of Dianxianning Tablets combined with Oxcarbazepine Tablets in treatment of epilepsy. Methods Patients (94 cases) with epilepsy in Geriatric Hospital of Hainan from January 2021 to January 2022 were divided into control and treatment groups according to the computer random arrangement method, and each group had 47 cases. Patients in the control group were po administered with Oxcarbazepine Tablets, the initial dose was 1 tablet/time, twice daily, and the drug dose was increased every other week by 2 tablets each time, and divided into 2 oral doses, and the maintenance dose was 2-8 tablets daily. Patients in the treatment group were po administered with Dianxianning Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the frequency of tonic seizures and clonic seizures, the number of epileptiform discharges, the number of involved leads, and the spike index, the serum levels of NSE, IL-1β, and TNF-α in two groups were compared. Results After treatment, the total effective rate of the treatment group was 91.49%, while the total effective rate of the control group was 74.47%, and the difference between the groups was statistically significant (P < 0.05). After treatment, the frequency of tonic seizures and clonic seizures in two groups was significantly lower than that in the control group (P< 0.05). After treatment, the frequency of tonic and clonic seizures in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the number of epileptiform discharges, the number of involved leads, and the spike index in two groups were significantly decreased (P < 0.05). After treatment, the number of epileptiform discharges, the involved leads, and the spike index in the treatment group were lower than those in the control group (P< 0.05). After treatment, the serum levels of NSE, IL-1β, and TNF-α in two groups were lower than that before treatment (P < 0.05), while the serum levels of NSE, IL-1β, and TNF-α in the treatment group were lower than those in the control group (P < 0.05). Conclusion Dianxianning Tablets combined with Oxcarbazepine Tablets in treatment of epilepsy can significantly improve the clinical efficacy of epilepsy, alleviate epilepsy symptoms, abnormal brain discharge, and inflammatory damage to nerve cells.

R971

海南省自然科學(xué)基金資助項(xiàng)目（818MS163）